Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources Group
High Willingness To Prescribe Otezla May Be Attributed To The Product's Oral Administration, Novel Mechanism Of Action And Favorable Safety Profile, According to Findings from Decision Resources Group
BURLINGTON, Mass., Aug. 4, 2014 Decision Resources Group finds that at one month post commercial availability, surveyed U.S. rheumatologists have each prescribed Celgene's Otezla to an average of two psoriatic arthritis (PsA) patients. Rheumatologists are still reserving Otezla for more difficult-to-treat patients as most PsA patients who have been prescribed Otezla have moderate or severe PsA. The most likely candidates for Otezla are PsA patients who would be switching from an anti-tumor necrosis factor (TNF) inhibitor or alternate MOA biologic or those who would be adding Otezla to a conventional disease-modifying antirheumatic drug (DMARD). When asked, one-third of surveyed rheumatologists see Otezla fitting into their treatment algorithm after failure of two biologics. However, when asked not to consider price as a factor, more than a quarter of rheumatologists would prescribe Otezla to new-start patients who are naive to conventional DMARD or biologic therapy.
Other key findings from the report entitled LaunchTrends®: Otezla (Psoriatic Arthritis) (Wave 1) 2014 (US):
Comments from Decision Resources Group Senior Data Analyst Elvina Wardjiman:
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
For more information, contact:
Decision Resources Group
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
©2012 PR Newswire. All Rights Reserved.